ReviewNeurology Series Editor, William J. Mullally, MDParkinson's Disease and Parkinsonism
Section snippets
Clinical Significance
- •
Parkinson's disease is the second most common neurodegenerative disorder with only Alzheimer's disease being more prevalent.
- •
It is defined primarily by its motor symptoms including tremor, bradykinesia and akinesia but may demonstrate a number of non-motor symptoms such as cognitive decline, depression, anxiety, sleep disturbance and dysautonomia.
- •
Treatment of the motor symptoms is accomplished primarily by dopaminergic medications or, more recently, with deep brain stimulation.
Clinical Presentation
Parkinson's disease is manifested by motor and nonmotor symptoms. The classic findings of Parkinson's disease are motor symptoms. These were described in the paper by Hoehn and Yahr6 in 1967 looking at 183 Parkinson's patients. They include resting tremor, bradykinesia, postural instability, and rigidity. Parkinson's disease frequently presents with tremor, usually unilateral. The tremor is typically seen in one extremity initially (sometimes involving only one finger or the thumb). The tremor
Pathology
The pathological hallmark of Parkinson's disease is depigmentation of the substantia nigra and locus coeruleus with neuronal loss in the pars compacta of the substantia nigra. Both apoptosis and autophagy are involved in the process.25 Neuronal loss is also seen in the basal nucleus of Meynert and the dorsal motor nucleus of the vagus nerve. In affected areas, Lewy bodies, which are eosinophilic cytoplasmic inclusion bodies containing alpha synuclein, are noted. The primary cause of Parkinson's
Pharmacologic Treatment
The decision of when to treat a patient with Parkinson's disease is made in collaboration with the patient. When symptoms affect the quality of life (the ability to work or socialize), treatment is started. There is no compelling evidence that starting treatment early has any impact on the progression of the disease, and no treatment confers neuroprotection. The decision to treat is based on the impact of symptoms.
Levodopa was the first effective medication for Parkinson's disease and is still
Functional Neurosurgical Treatment
Before levodopa became the primary treatment for Parkinson's disease (in the early 1960s), some patients received lesions to the thalamus pioneered by Cooper and others.30., 31. Surgical treatment of Parkinson's disease was largely abandoned until the limitations of dopaminergic therapy became apparent. These included motor fluctuations, dyskinesias, hallucinations, and intractable tremor.
There was a resurgence of stereotactic ablative surgery to the thalamus, subthalamic nucleus, and globus
Lewy Body Disease
Lewy body disease is akin to classic Parkinson's disease, clinically and pathologically. Pathologically, in addition to Lewy bodies being found in the striatum, there is widespread involvement of Lewy bodies in cortical neurons, with a relative paucity of the neurofibrillary tangles and amyloid plaques associated with Alzheimer disease.36., 37. The diagnosis is clinical and consists of the appearance of parkinsonian symptoms, dementia, hallucinations and delusions, frequently fluctuating with
References (55)
- et al.
Parkinson’s disease from pathology to molecular disease mechanisms
Free Radic Biol Med
(2013) - et al.
Gender effects on non-motor symptoms in Parkinson’s disease: are men more at risk?
Parkinsonism Relat Disord
(2017) - et al.
Gender differences in Parkinson’s disease depression
Parkinsonism Relat Disord
(2017) - et al.
Dementia in Parkinson’s disease: is male gender a risk factor?
Parkinsonism Relat Disord
(2016) - et al.
An investigation into the effects and prognostic factors of cognitive decline following subthalamic nucleus stimulation in patients with Parkinson’s disease
J Clin Neurosci
(2017) - et al.
Premotor signs and symptoms of multiple system atrophy
Lancet
(2012) - et al.
Gender differences in Parkinson’s disease
J Neurol Neurosurg Psychiatry
(2007) - et al.
Incidence of Parkinson’s disease: variations by age, gender, and race/ethnicity
Am J Epidemiol
(2003) - et al.
Parkinson’s disease and exposure to agricultural work and pesticide chemicals
Neurology
(1992) - et al.
A meta-analysis of coffee drinking, cigarette smoking and the risk of Parkinson’s disease
Ann Neurol
(2002)
Parkinsonism: onset, progression and mortality
Neurology
Lapeyre-Mestre et al. A study of salivary secretion in Parkinson’s disease
Clin Neuropharmacol
What is wrong with balance in Parkinson’s disease?
J Mov Disord
The prevalence of smell loss in Parkinson’s disease – a multicenter study
Parkinsonism Relat Disord
Environmental, life style and physical precursors of clinical Parkinson’s disease: recent findings of the Honolulu-Asia aging study
J Neurol
Excess burden of constipation in Parkinson’s Disease: a pilot study
Parkinsonism Relat Disord
Gastric emptying and gastric motility in patients with Parkinson’s disease
Mov Disord
Prevalence of orthostatic hypotension in Parkinson’s disease
J Neurol Neurosurg Psychiatry
Non-motor symptoms in Parkinson’s disease
Eur J Neurol
Urinary dysfunction in early and untreated Parkinson’s disease
J Neurol Neurosurg Psychiatry
A systemic review of prevalence studies of depression in Parkinson’s disease
Mov Disord
The natural history of depressive symptoms in patients with incident Parkinson’s disease: a prospective cohort study
J Neurol
Depression and anxiety related subtypes in Parkinson’s disease
J Neurol Neurosurg Psychiatry
“Pure apathy” and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study
Neurosci Biobehav Rev
A systematic review of prevalence studies of dementia in Parkinson’s disease
Mov Disord
Risk and incidence of dementia in a cohort of older patients with Parkinson’s disease in the UK
Mov Disord
Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease
Histol Histopathol
Cited by (340)
Plasma oxylipin profiles reflect Parkinson's disease stage
2024, Prostaglandins and Other Lipid MediatorsIncreasing incidence of Parkinson's disease in patients with epilepsy: A Nationwide cohort study
2024, Journal of the Neurological SciencesStereotatic radiosurgery for the treatment of motor symptoms in Parkinson's disease: A systematic review
2024, Journal of Medical Imaging and Radiation SciencesCRISPR/Cas9 system and its applications in nervous system diseases
2024, Genes and DiseasesTherapeutic potential of Coumarin-polyphenolic acid hybrids in PD: Inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation
2024, Bioorganic and Medicinal Chemistry Letters
Funding: None.
Conflicts of interest: None.
Authorship: MTH was the sole author of the manuscript.